Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DF5R7E
|
|||
| Drug Name |
Romilkimab
|
|||
| Synonyms |
SAR156597
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Idiopathic pulmonary fibrosis [ICD-11: CB03.4; ICD-10: J84.1; ICD-9: 516.3] | Phase 2 | [1] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02345070) Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (ESTAIR). U.S. National Institutes of Health. | |||
| REF 2 | A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.